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S u m m a ry  Tacalcitol is a vitamin D analogue which has been developed for the therapy of psoriasis vulgaris.
treatment with a twice daily application of 2 u g /g  ointment
randomized left comparison 
ition of a 4 wg/g
ointment
male and female
d desquamation was influenced significantly more by tacalcitol ointment than by placebo 
< 0-0001) at every control point, starting from week 2. With regard to the individual symptoms 
desquamation, infiltration and erythema, the treatment with tacalcitol was also superior to 
cebo treatment beginning at week 2. Qualitatively, the same results were obtained with the 
iference assessment of both treated body sides and also the global assessments of efficacy and 
lefit. Symptoms of local skin irritation which may be related to the active compound or the
ointment base were reported by 12-3% of patients. In only one patient, irritation required
discontinuation of tacalcitol treatment. Laboratory criteria, including serum calcium, serum 
phosphate and serum levels of calcitonin, parathormone, 1 a,24-dihydroxy vitamin 1), and 25-
hydroxyvitamin D3 , did not reveal 
Furthermore, the dob al assesvsment
treatment.
c\ r\
demonstrate that the once daily application of a 4 /tg/g
an efficacious therapy for psoriasis vulgaris in Caucasian patients, and that its tolerance is good, 
wherever the lesion is located, including on the face.
Several antiproliferative or immunomodulatory drugs, 
such as dithranol, topical corticosteroids, 
methotrexate, cyclosporin A, or psoralens with UVA,
0
have proven to be effective in the therapy of psoriasis 
but each of them is associated with different disadvan­
tages. Therefore, new principles of therapy are desir­
able. Recently, attention has again been focused on the 
treatment of psoriasis with vitamin D analogues. Interest 
first arose when a patient’s psoriasis improved while his 
osteoporosis was being treated with 1  a-hydroxy-vitamin 
D3. Several studies have demonstrated that active 
vitamin D3 inhibits epidermal proliferation, enhances 
normal keratinization and interferes with cutaneous
inflammation."' In view of the fear of the 
potential of vitamin I) 3 derivatives, which implies the risk 
of serious adverse events such as the calcification of such
psoriatic treatment with vitamin D had to wait until new 
analogues with a reduced calcipotropic potential became 
available. In many countries, caldpotriol has been intro­
duced for the treatment of psoriasis. This vitamin D 
analogue also inhibits the proliferation of keratinocytes 
and induces their differentiation but has a much less 
pronounced effect on the calcium metabolism. 5 Tact 
(la,24-dihydroxy vitamin for review 
et al.4) is another synthetic of
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( la ,2 5-dihydroxy vitamin D3), the most active metabo­
lite of vitamin D. The affinity of tacalcitol to the vitamin D 
receptor in human keratinocytes is slightly higher than 
that of naturally occurring vitamin D. The effect that 
tacalcitol exerts on the proliferation and differentiation of 
cultured epidermal cells is also comparable with or 
slightly more pronounced than that of calcitriol. This 
has been shown in murine epidermal cells as well as in 
normal human keratinocytes and in those derived from 
psoriatic lesions. Clinical studies have shown good 
therapeutic efficacy in Japanese psoriatics with a twice 
daily application of a 2 /ig/g tacalcitol ointment.
With regard to safety, there were neither changes in 
the tested laboratory criteria nor were there any serious 
drug-related adverse events when studies were per­
formed with a maximum treatment duration of 1 2  
weeks. Drug-related adverse events were also not 
observed in two clinical studies where a 4 yug/g tacalcitol 
ointment was applied twice daily for up to 4 weeks. 1 3, 14
1 c
Furthermore, in a safety confirmation study where up 
to 80/^g/g tacalcitol were applied once daily in an 
ointment for 7 consecutive days to the skin of both 
healthy adults and psoriasis patients, no relevant fluc­
tuations were observed in the level of serum calcium, 
serum phosphate or serum creatinine. Tacalcitol was 
detected in the blood of one healthy volunteer but was at 
below the detection limit (25 pg/ml) in all other cases. No 
effect on intrinsic vitamin D metabolism was observed. 15
The objective of the present double-blind, placebo- 
controlled clinical study was to show whether tacalcitol 
ointment is also efficacious and safe in the therapy of 
Caucasian psoriatics, as the above-mentioned data were 
derived from Japanese patients. Furthermore, it was 
desirable to reduce the frequency of application from 
twice daily to once daily in order to enhance patients’ 
compliance. A concentration-finding study, 1(1 performed 
as a psoriasis plaque test, revealed that a once daily 
application of an ointment containing 4 /ig/g
andomized
left comparison. Before the start of treatment, a 2-week 
wash-out period was required for all patients. Treat­
ment consisted of a once daily, randomized application 
of either tacalcitol ointment or the base without active 
substance (hereafter referred to as placebo) to the 
selected psoriatic test lesions. Lesions were treated 
until they cleared but for not more than 8  weeks. 
There was a post-treatment follow-up period lasting 
until the onset of a relapse or for a maximum of 4 
weeks. There were controls at weeks - 2 ,0 ,  2 ,4 , 6 , 8  (or 
at the end of treatment) and 1 2  (or at the onset of a 
relapse). Medical ethical committee approval was 
obtained in each study centre and patients were 
included after having given informed consent.
Patient selection
Male and female patients, aged 1 5 -8 0  years, with 
stable plaque psoriasis were considered for entry into 
the study. Females were not allowed to be or to become 
pregnant during the trial. Patients with an increased 
serum calcium or serum phosphate level (>10-5 mg/ 
100 ml and/or >4-5 m g/100 ml, respectively) were 
excluded, as were patients who had received systemic 
or topical antipsoriatic treatment over a period of 2  
months or 4 weeks respectively, prior to the start of the 
study. Other exclusion criteria were serious diseases, the
necessity for concomitant therapy
below), known allergy to any ingredient of the study 
medication, participation in another clinical trial within 
4 weeks prior to the start of this study, or expected poor 
compliance (e.g. drug addiction). No calcium supple­
ments or drugs influencing the calcium metabolism
2d. The use of , barbiturates,
phenytoin and non-steroidal anti-inflammatory drugs 
were also prohibited. The test areas were only allowed 
to be treated with either white petrolatum or an emol-
or more provided the best efficacy. The 
ointment has proven to have very good skin Y
(Meyer-Rohn et a l, il communication). Thus, the
wash-out
period, 
white petrolatum,
and the follow-up
, 2 -3 %  salie
t
m
prerequisites were fulfilled to perform a phase III study 
with the aim of investigating the efficacy and safety of a 
once-daily application of a 4 /ig/g tacalcitol ointment in 
the therapy of psoriasis vulgaris in Caucasian patients.
illowed to be applied to psoriatic lesions other than 
the test areas throughout the whole study period.
Psoriatic lesions chosen as test areas were allowed to 
be localized anywhere but on the scalp. They were
to have a score sum of >5 of
Methods
The study was designed as a multicentre, double-blind,
scores see below) for erythema, infiltration and desqua­
mation, and at least moderate intensities (score 2 ) for 
erythema and desquamation. The difference of the score
sums 5 for tacalcitol and placebo 
treatment had to be ^  1. The test lesions also had to be
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comparable with regard to localization (almost sym­
metrical) and area (for each treatment up to 1 0 % of 
total body surface).
Study medication and evaluation
The placebo consisted of paraffin oil, diisopropyl adipate 
and white petrolatum. Tacalcitol ointment additionally 
contained é/Âg/g  tacalcitol (la-24-dihydroxycholecal- 
ciferol). At the beginning of the study (week - 2 )  
demographic data (sex, age, height and weight) and 
anamnestic data (diagnosis, localization and area of 
lesions, outbreak of disease, duration of last attack, 
previous treatment, other diseases and their treatment) 
were gathered. Furthermore, the parameters for the 
efficacy and safety evaluations (see below) were 
assessed. Whenever the severity was described, the 
following scoring system was applied: 0 , none; 1 , 
slight; 2 , moderate; 3, severe; 4, very severe.
The primary efficacy criterion was the score sum of 
erythema, infiltration and desquamation, which was
(McNemar) was used for binary data, and the paired 
Wilcoxon test was used for categorized data with 
ordered categories. The laboratory data were analysed 
by the Sign test, Wilcoxon ranking test or Stuart- 
Maxwell test and partly by the i-test. There was a 
statistical analysis of all randomized patients with at least 
one post start of treatment measurements (‘intention-to- 
treat’) and of all patients who were treated according to 
protocol (‘per protocol’).
The safety assessment comprised: (i) adverse drug 
events, assessed at weeks 2, 4, 6  and 8 ; (ii) global 
assessment of tolerance by investigator and patient ( 1 , 
very good; 2, good; 3, moderate; 4, poor), made at week 
8 ; (iii) haematology (white blood cell count, red blood 
cell count, platelet count, haemoglobin, haematocrit) 
evaluated before and at the end of treatment; (iv) blood 
chemistry (serum calcium, serum phosphate, serum 
creatinine, SGOT, alkaline phosphatase, LDH), evalu­
ated at weeks —2, 0, 2, 4, 6  and 8 ; (v) serum calcitonin, 
parathormone, 1  o;,25-dihydroxyvitamin Dj and 25- 
hydroxy vitamin D3 assessed at four centres before and
assessed before the start of treatment (week 0 ) and at 
every control visit during the treatment period (weeks
treatment
2, 4, 6 , 8 ). This criterion was chosen as it is part of the 
PASI score but does not include the localization and Results
extent which was not considered to be useful in an 
intraindividual comparison with a maximum area of 
1 0 % of total body surface.
The secondary efficacy criteria were: (i) individual 
scores for erythema, infiltration, desquamation and 
pruritus; (ii) preference assessment (left better than 
right, left equal to right, left worse than right); (iii) 
time to complete healing; (iv) area of test lesions; (v)
Patients' details
One hundred and twenty-two patients were included in 
the intention-to-treat analysis and the safety analysis, 
and, as 19 patients were protocol violators, 103 patients 
were included in the per-protocol analysis. Protocol viola-
:ind/or
medic
global assessment of efficacy made by investigator and 
patient (1 , very good; 2, good; 3, moderate; 4, poor); (vi) 
assessment of benefit based on the patient’s experience 
(scale from 0 , ‘not beneficial’, through 1 0 , ‘exceedingly 
beneficial’); (vii) post-treatment relapse of 
lesions (by means of the individual scores for erythema, 
infiltration, desquamation and pruritus at week 1 2 ).
some
patient did not return (three patients), patient refused 
further participation (one patient), termination of study 
without known reason (one patient). Sixty patients were 
randomized to tacalcitol 
and 62 patients to placebo Ireal-
m ent In total 76 male and 46 female patients were
Statistical tests and safety assessment
For the primary efficacy criterion, the significance of 
difference was evaluated by means of the two-sided 
Wilcoxon matched-pairs signed-ranks test, the effect 
size measure being the Mann-Whitney statistic P 
(X < 7). The Mann-W hitney statistic is assessed as: 
0-50, equal; 0.56, small difference; 0.64, medium-sized
included. The
(mean ±  SD) years.
78-0 ±  15-25 kg
r i  n
8  ±  1 3 • 6  9
a body
of 173-1 ± 8 cm.
They had had psoriasis for 233*5 ±  1 7 5-9 months and
the duration of the of psoriasis was
28-4 ±  74-8 months. On the right side of the body the 
test lesions comprised 5 - 6  ±  2 -6 % of the total body sur­
face and on the left side they comprised 5 • 5 ±  2 • 7% of 
the total body surface.
0.71, large If P were
calculated for the secondary criteria, a symmetry test
In the majority of patients 
treatment with tacalcitol
5 % ), Lest lesions for 
or placebo were
(ri 1996 British Association of Dermatologists, British Journal of Dermatology, 1 55, 758-765
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localized on more than one part of the body (arbitrarily 
divided into face, arms, legs, dorsal and ventral trunk). 
The test lesions were predominantly localized on arms 
and/or legs, but in a quarter of all patients (24-6%), test 
lesions were localized on the face or on the face plus 
other parts of the body.
The pretreatment intensity of the individual criteria was 
judged as severe or very severe in more than half of the 
test areas (59%; desquamation; 65% infiltration; 72%; 
erythema). There was no pruritus in 29% of the test 
areas and in the majority of cases it was only slightly or 
moderately expressed (about 53%).
By the end of treatment (week 8 ), the score sum for 
erythema, infiltration and desquamation (primary effi­
cacy criterion) had decreased on average by 4*0 score 
points (median: 5-0) after tacalcitol treatment and by 
2-3 score points (median: 3-0) after treatment with 
placebo (per-protocol group). The superiority of tacalci­
tol vs. placebo treatment was significant (P < 0-0001) 
from week 2  until the end of treatment. Using the 
Mann-Whitney effect size measure, it could be shown 
that the difference between the two treatments was 
large (P[X < Y ] ^  0-71) at every control visit whereas 
there was equality between the test areas at baseline. 
This could be demonstrated for the per-protocol patients
(n 103 patients; see Fig. 1) as well as for those in the
intention-to-treat group (n =  122 patients). Further­
more, these large differences were maintained when 
the data of each centre were analysed separately (centres 
with fewer than four patients were pooled). The differ­
ences were statistically significant at centres with more 
than nine patients.
The secondary efficacy criteria characterized further 
the response to tacalcitol and placebo treatment, (i) The 
intensity of the individual criteria of erythema, infiltra­
tion and desquamation is lower in the 
treated with tacalcitol ointment than in those treated 
with placebo. The superiority of tacalcitol was confirmed 
by the Mann-Whitney statistic: for erythema there was 
a medium-sized difference at week 2  (P[X < Y] 
which became large [P[X <  Y] =  0-72) from week 6 ;
those treated with placebo (Fig. 2 ). This difference was 
large beginning at week 2  for both the per-protocol
group and the intention-to-treat group, (iii) Time to
k
complete healing could not be assessed as the duration 
of treatment ( 8  weeks) was for most patients too short to 
permit complete healing, (iv) The area of test lesions 
changed by less than 1 % during treatment with either 
of the preparations. Statistically, there was a small to 
medium-sized difference at week 8  (data not shown) 
which is without clinical relevance in this case, (v) 
Global assessment of efficacy revealed conformity 
between the investigator and the patient in 78'6% of 
cases and was greatly in favour of tacalcitol ointment
vs. placebo (P < 0*0001, P[X < Y 0-82). The data of
the per-protocol patients are summarized in Figure 3; the 
data of the intention-to-treat group are qualitatively the
Median score sum
10 «
0 2 4 6 8
for infiltration the difference could be qualified as large 
from week 4; for desquamation there was a medium­
sized difference at week 2  and a large difference at week 
8 . For pruritus, however, there were only small differ­
ences at all control points after the start of treatment, (ii)
assessment revealed that the 
treated with tacalcitol ointment were better
Weeks
Figure 1. Median score sum of erythema, infiltration and desquama­
tion during treatment with tacalcitol ( -A -)  or with placebo (-- * 
in per protocol patients. The difference between treatments is large 
(P[X < Yj 2* 0 7 1 ) according to the Mann-Whitney statistic, and 
significant (/’ < 0-0001) at every time point except baseline (week 
0) where the score sums are equal.
© 1996 British Association of Dermatologists, British Journal of Dermatology, 135, 758-765
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same, (vi) By means of a scale wit h the two extremes ‘not 
beneficial’ (score 0 ) and ‘exceedingly beneficial’ (score 
1 0 ), the benefit of tacalcitol ointment was assessed with 
score 7  (median) where the benefit of placebo was 
assessed with score 4 (median). The difference between 
these assessments is obviously large and it is statistically 
significant (P <  0-000.1). (vii) An exact evaluation of 
psoriatic relapses could not be made as in most cases the 
test lesions had not cleared during the 8  weeks’ treat­
ment. Nevertheless, of 97 patients who underwent a 
follow-up examination, 34 patients (35*1%) had an 
aggravation and 63 patients (64-9%) had no aggrava­
tion at all. The aggravation occurred bilaterally in 2 8  of 
these 34 patients and unilaterally in six patients (three 
tacalcitol, three placebo).
Tolerance and safety
Fifteen of the 122 intention-to-treat patients (12-3%)
% patients
80
■
I ft*"
r
r
I-*
a r
2 4 6 8
W eeks
Figure 2. Preference assessment. This was made by means of a right 
left comparison of the test lesions in all per-protocol patients.
tacalcitol better; W, equal; Ü, placebo better.
reported one or more symptoms of skin irritation. Six 
patients complained of a burning sensation, seven 
patients of pruritus, there were six cases of skin rashes 
(one with rhagades and erosion), and one case of 
rhagades. Skin irritation occurred bilaterally in four 
patients and unilaterally in five patients (three tacal­
citol, two placebo). In six cases the body side was not 
documented. In the three patients where only the 
tacalcitol-treated test areas were affected, there were 
complaints of slight to severe pruritus in some of the test 
areas. This was accompanied by pustules in some of the 
test lesions in one patient, by redness and heat sensation 
in one other patient. Only one of the 15 patients 
discontinued treatment of the irritated lesions, but not 
of the other test lesions.
Five patients of the intention-to-treat group (4*3%) 
reported an adverse event. One patient had diarrhoea, 
one suffered from nausea, in one case a haematoma was 
diagnosed, in one there was slight circulatory reaction 
and fatigue, and one patient’s skin was dry. The symp­
toms lasted for several days, but did not require treat­
ment or a withdrawal of the study drugs. None of these 
events was considered to be drug-related.
Laboratory investigations revealed no clinically rele­
vant effects. In the haematology parameters the Sign 
test showed that there were no important changes from 
baseline. With regard to the blood chemistry criteria, 
the Sign test did not reveal any important changes from 
baseline, whereas the Stuart-Maxwell test showed a
although clinically irrelevant deviation 
from normal in alkaline phosphatase at week 2, In 
addition to the statistical analysis, the data of each 
patient were analysed and did not show any clinically 
relevant changes. The serum calcium levels are shown
Very good
“ I»»1 «yi.H»
Good
IOB
Moderate
Poor
0 10 20 30 40 50 60 70  %
Figure 3. Global assessment of efficacy. The assessment of efficacy of
treatment with tacalcitol ointment (■) or placebo (El) in the per- 
protocol group as made by the investigator is given.
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Figure 4. Indicators for calcium metabolism (mean ±  standard
deviation), (a) Serum calcium levels (—x in 122 patients, all
centres), (b) Serum calcitonin (x: jpg/ml|), parathormone (O); [pg/ 
mlj), 1 cv2 5-dihydroxyvitamin l)5 (■; [pg/ml]), 2 5-hydroxy vitamin 1), 
(A; (ng/ml)). The respective normal ranges are given as bac 
of the statistical values (of 84 patients, four centres).
in Figure 4a. No significant changes (Sign test) were 
observed during the 8  weeks’ treatment period. In 84  
patients serum calcitonin, parathormone, 2 5-hydroxy- 
vitamin D$ and 1,2 5-dihydroxyvitamin D } were moni-
No changes in
(Wilcoxon ranking test, i-test) were found (Fig. 4b).
The tolerance of tacalcitol treatment was considered
by ì investigator to or very in 1 18 of
119 patients (99-2%), and the corresponding value for 
the placebo treatment was 98-3%. The patients con­
firmed good or very good tolerance in 113 of 118 cases 
(95*8%) for tacalcitol and in 1 1 1  cases (94*1%) for the 
placebo.
Discussion
The data demonstrate the efficacy of this tacalcitol oint­
ment in the treatment of psoriasis vulgaris in Caucasian
patients and its superiority vs. the base without the active 
substance. It was possible to show the efficacy by means 
of a set of different criteria which either describe the
symptoms
impression
of the disease. Most of the criteria revealed a large 
difference between the tacalcitol treatment and the 
placebo treatment, frequently apparent from the first 
control visit. By means of statistical analysis per study 
centre it could be shown that only 1 2  patients were
r demonstr
difference between treatments. The influence of tacalcitol 
on pruritus and area of test lesion was only slightly better 
than that of placebo. However, these small differences 
were without clinical relevance. For the area of the test
could have been expectedlesions an indirect 
through the action on the efficacy criteria. However, 
the duration of treatment in this study might have been 
too short to influence the area of the test lesions. A recent 
publication states18 that individual lesions resolve with­
out decrease in area until clearance occurs. In the 
present investigation, a consistent observation was the 
pronounced reduction of all efficacy scores including 
erythema. The intensity of erythema decreased from 
mainly very severe to mainly moderate or slight after 
tacalcitol treatment, whereas placebo treatment only 
reduced the erythema to mainly severe or moderate
With regard to safety, there were neither any drug- 
related serious adverse events nor were there deviations 
in the laboratory parameters which were of clinical 
relevance. From all safety data, it can be concluded 
that there was no indication of any influence on the 
systemic calcium metabolism. Hypercalcaemia has been 
observed for vitamin Dj analogues. 1 y F
on the long-term safety of tacalcitol are in 
Symptoms of local skin irritation were observed or
case of pruritus) by 1 5 patients. In this 
it is relevant to note that the patients were
to treat face "es, i.e. areas’ S’
are relatively susceptible for irritation to vitamin 1 ) 5 
analogues. It is possible that the irritations are related to 
the study medication. Nevertheless, they did not occur 
more frequently in the taealcitol-treated areas than in 
the placebo-treated lesions. It should be noted that 
pruritus is also a symptom of psoriasis. In some patients
-T pruritus wasit was i to
part of the manifestation of this disease or a drug-related 
adverse event. In spite of the reported local skin irrita­
tion, the tolerance was assessed as good or very good in
the of cases. It was rc for
(c) 1996 British Association of Dermatologists, British journal of Dermatology, 135, 758-765
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further treatment with tacalcitol that the therapy of 
psoriatic lesions on the lace with this medication was 
well tolerated. Of 30 patients whose test areas were also
symptoms oflocalized on the face, only two re 
local skin irritation there.
Calcipotriol (50/ug/g)  in ointment is the vitamin D3 
analogue which has been available in many countries 
for 3 years. This analogue has proven to be effective, has 
been well accepted although irritation of the skin was a
limitation, in up to 25% of the patients. 19,23 In Japan, an
ointment with tacalcitol has been available for 2 years 
and has proven to be effective and well-tolerated; less 
than 1% of the patients showed irritation of the skin.4 
Caicitriol (3/ig/g) in ointment twice daily has been 
reported to be effective in the treatment of psoriasis.“ 
However, again irritation limits the use of this com­
pound in up to 15% of the patients (van de Kerkhof, 
personal communication). Up to 3% of the patients had 
to discontinue treatment due to severe irritation (van de 
Kerkhof, personal communication). It has been difficult 
to make a direct comparison between the vitamin D3 
analogues with respect to efficacy and tolerance as no 
comparative studies are available to date. However, the 
present study suggests that tacalcitol 4 /ig /g  in oint­
ment, applied once daily has a relatively low potential to 
induce irritation.
It can be concluded from the present investigation 
that a once daily topical treatment with a 4/Ug/g
acious in the therapy oftacalcitol ointment is 
psoriasis vulgaris in the majority of Caucasian 
patients. Of course it would be desirable to have data 
of long-term therapy as well as data of extensive 
treatment (more than 10% of body surface). The 
present study, however, does not provide any evidence 
of a modulation of systemic calcium metabolism. In 
view of the relatively low irritancy and the marked 
effect on erythema it is attractive to speculate that 
tacalcitol may become a mainstay in the treatment of 
flexural and facial psoriasis. Tacalcitol ointment there­
fore has the potential to establish itself as a valuable 
therapeutical option in the spectrum of 
pharmaceutics.
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